CD20, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD20, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD20, Human |
| Clone | REA780 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | phycoerythrin (PE) conjugate |
| Size | 30 tests in 60 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD20 Antibody, anti-human, PE, REAfinity™. Clone REA780 recognizes the CD20 antigen, a non-glycosylated transmembrane protein of 33-37 kDa that is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca 2)+ channel and might function in the regulation of local responses during B cell activation. | Additional information: Clone REA780 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, Ly-44 |
| Gene, Accession # | Gene ID: 931 |
| Catalog # | 130-111-524 |
| Price | $110 |
| Order / More Info | CD20, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Countouriotis, T. B. et al. (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20 (3): 215-229. | Polyak et al. (2002) CD20 Workshop Panel report. In: Leucocyte typing VII, Oxford University Press.: . | Lamprecht, B. et al. (2008) Aberrant expression of the T?2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112 (8): 3339-3347. | Maxwell, S. A. et al. (2009) 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J. Biol. Chem. 284 (33): 22379-22389. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies